

**OPTN Histocompatibility Committee  
Meeting Summary  
April 08, 2025  
Webex Meeting**

**Gerald Morris, PhD, MD, Chair  
Kelley Hitchman, PhD, MS, Vice Chair**

## **Introduction**

The Histocompatibility Committee (“Committee”) met via WebEx teleconference on 04/08/2025 to discuss the following agenda items:

1. Updates
2. Table Update Discussion
3. ABO Molecular Testing Project Discussion

The following is a summary of the Committee’s discussions.

### **1. Updates**

**No decisions were made.**

#### Summary of Presentation:

The Chair presented updates for timelines on the Table Update project. It was mentioned that the guidance document is awaiting next steps. The Chair mentioned that serotypes are not being added to this table update because the Committee is waiting for World Health Organization guidance.

### **2. Table Update Discussion**

**No decisions were made.**

#### Summary of Discussion:

The Committee reviewed goals of the table update project, which includes updating C:04:09L and Table 4-16 for p-groups. Following further guidance from IT support, the Committee will be reviewing table updates at the next meeting.

### **3. ABO Molecular Testing Project Discussion**

**No decisions were made.**

#### Summary of Discussion:

The Chair reviewed information and timeline for the ABO molecular testing project. They stated the tentative plan is to move forward with a requirement of ABO molecular testing usage when blood typing discrepancies occur, especially after mass transfusions.

#### Summary of Discussion:

A member asked about current usage of ABO molecular testing. The Chair stated that questions about usage may be answered in an upcoming data request. Further, while he estimates around two-dozen already use this testing, he stated that feasibility will be an important part of this project. A member mentioned that other samples for HLA typings should be considered, especially regarding non-leukocyte reduced blood.

A member said that states may have certain regulatory licensing requirements, such as separate qualifications for histocompatibility laboratories and blood banks/transfusions, that could make ABO molecular testing requirements difficult. The Committee decided they will further discuss and investigate the impacts of state regulations.

The Chairs requested to ask the Organ Procurement Organizations around their ABO molecular genotyping feasibilities.

### **Upcoming Meeting**

- May 12, 2025

## Attendance

- **Committee Members**
  - Michael Gautreaux
  - John Lunz
  - Ryan Pena
  - Darryl Nethercot
  - Bobbie Rhodes-Clark
  - Crystal Usenko
  - Qingyong Xu
  - Helene McMurray
  - Dave Pinelli
  - Kelley Hitchman
  - Andres Jaramillo
  - Hemant Parekh
  - Tiffany Bratton
  - Jerome Saltarelli
  - Jerry Morris
- **SRTR Staff**
  - Rajalingam Raja
- **UNOS Staff**
  - Jamie Panko
  - Betsy Gans
  - Amelia Deveraux
  - Matt Cafarella
  - Thomas Dolan